AMRI bounces off lows after Bristol-Myers ends BMS-820836 development The shares are off the initial spike low following the announcement that Bristol-Myers (BMY) was ending development of BMS-820836. The company has said it expects no impact to guidance as a result of this action. At the current price of $10.89, the stock is down over 13.4%. The low of the session at $9.82 is support. Resistance is at $11.47.
News For AMRI From The Last 14 Days
Check below for free stories on AMRI the last two weeks.